Stuart Dollow

Vermilion Life Sciences Ltd

Stuart is Chair of the Advisory Committee on Clinical Excellence Awards (ACCEA). He is a fully GMC registered physician, who trained in General Medicine and General Practice before gaining many years’ experience in senior leadership roles at Roche, GlaxoSmithKline, Norgine, Takeda and UCB. He is the Founder of Vermilion Life Sciences, which provides consultancy services to reduce the time and cost of medicines development to improve patient access.
Stuart is also an Authority Member of the Human Tissue Authority, a Board Trustee of the Faculty of Pharmaceutical Medicine, and has worked as an external ‘Champion'' for the UK Government''s Office for Life Sciences, Accelerated Access Review.

dont miss

Reengineering Medicines Development

Exploring opportunities to reduce the cost and time of medicines development. How patient input, digital tools and real world data in real time can facilitate adaptive licensing and early regulator and payer discussions to generate early access.

EVEN MORE SEMINARS

  • James Flanagan: Speaking at the Oncology Convention

    James Flanagan
    Imperial College London

    Epigenetic biomarkers for platinum response in ovarian cancer

  • Professor Hisham Mehanna: Speaking at the Oncology Convention

    Professor Hisham Mehanna
    InHANSE, Institute of Cancer and Genomic Sciences, University of Birmingham

    Clinical trials that change patient care and the lessons learnt

  • Christopher Curtis: Speaking at the Oncology Convention

    Christopher Curtis
    The Swallows Head & Neck Cancer Charity

    From Cancer to the Palace in 6 years

  • Stuart Dollow: Speaking at the Oncology Convention

    Stuart Dollow
    Vermilion Life Sciences Ltd

    Reengineering Medicines Development

  • Professor Farzin Farzaneh: Speaking at the Oncology Convention

    Professor Farzin Farzaneh
    King’s College London

    Advanced Therapy Medicinal Products (ATMPs) for achievement of deeper and longer lasting immune mediated cancer remission